UBS Asset Management Americas Inc. held its stake in Chemed Corp. (NYSE:CHE) during the second quarter, Holdings Channel reports. The firm owned 10,931 shares of the company’s stock at the end of the second quarter. UBS Asset Management Americas Inc. owned about 0.07% of Chemed Corp. worth $1,490,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Institutional Trust Company N.A. boosted its stake in Chemed Corp. by 0.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 431,220 shares of the company’s stock worth $58,409,000 after buying an additional 1,831 shares in the last quarter. BlackRock Inc. boosted its stake in Chemed Corp. by 90.4% in the first quarter. BlackRock Inc. now owns 1,152 shares of the company’s stock worth $156,000 after buying an additional 547 shares in the last quarter. Commonwealth Equity Services Inc purchased a new stake in Chemed Corp. during the second quarter worth $906,000. M&T Bank Corp boosted its stake in Chemed Corp. by 2.2% in the first quarter. M&T Bank Corp now owns 3,052 shares of the company’s stock worth $413,000 after buying an additional 65 shares in the last quarter. Finally, BlackRock Group LTD boosted its stake in Chemed Corp. by 7.2% in the first quarter. BlackRock Group LTD now owns 22,610 shares of the company’s stock worth $3,062,000 after buying an additional 1,514 shares in the last quarter. Institutional investors and hedge funds own 98.64% of the company’s stock.
Chemed Corp. (NYSE:CHE) traded down 0.29% during mid-day trading on Thursday, reaching $138.47. 17,456 shares of the company were exchanged. The firm has a market capitalization of $2.24 billion, a P/E ratio of 21.96 and a beta of 1.17. The stock has a 50-day moving average of $138.38 and a 200 day moving average of $136.18. Chemed Corp. has a 1-year low of $124.77 and a 1-year high of $160.12.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings results on Monday, July 25th. The company reported $1.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.08. The company had revenue of $290 million for the quarter, compared to analyst estimates of $393.50 million. Chemed Corp. had a net margin of 6.93% and a return on equity of 24.12%. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.71 earnings per share. Equities research analysts forecast that Chemed Corp. will post $7.25 earnings per share for the current year.
CHE has been the topic of a number of recent analyst reports. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $155.00 price target on shares of Chemed Corp. in a report on Tuesday, September 27th. Zacks Investment Research cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Royal Bank Of Canada lifted their target price on shares of Chemed Corp. from $136.00 to $162.00 and gave the stock a “sector perform” rating in a research note on Wednesday, July 27th. RBC Capital Markets reiterated a “sector perform” rating and issued a $162.00 target price (up from $136.00) on shares of Chemed Corp. in a research note on Wednesday, July 27th. Finally, JMP Securities reiterated a “hold” rating on shares of Chemed Corp. in a research note on Sunday, September 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Chemed Corp. currently has an average rating of “Hold” and an average target price of $161.50.
In related news, insider Spencer S. Lee sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $141.67, for a total transaction of $283,340.00. Following the sale, the insider now directly owns 39,867 shares in the company, valued at $5,647,957.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Arthur V. Tucker, Jr. sold 3,089 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $143.88, for a total transaction of $444,445.32. Following the sale, the vice president now owns 3,234 shares in the company, valued at $465,307.92. The disclosure for this sale can be found here. Company insiders own 5.32% of the company’s stock.
Chemed Corp. Company Profile
Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.